ARZERRA
Total Payments
$144.7M
Transactions
2,073
Doctors
150
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $390,661 | 18 | 9 |
| 2022 | $58.6M | 439 | 37 |
| 2021 | $39.4M | 317 | 62 |
| 2020 | $19.1M | 381 | 42 |
| 2019 | $8.7M | 343 | 20 |
| 2018 | $7.9M | 270 | 18 |
| 2017 | $10.6M | 305 | 25 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $144.5M | 1,698 | 99.9% |
| Consulting Fee | $171,933 | 47 | 0.1% |
| Travel and Lodging | $16,762 | 86 | 0.0% |
| Food and Beverage | $10,884 | 236 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,132 | 4 | 0.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,120 | 1 | 0.0% |
| Education | $565.79 | 1 | 0.0% |
Payments by Type
Research
$144.5M
1,698 transactions
General
$211,397
375 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS | Novartis Pharmaceuticals Corporation | $72.6M | 0 |
| A RANDOMIZED DOUBLE BLIND DOUBLE DUMMY PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF OFATUMUMAB ADMINISTERED SUBCUTANEOUSLY VERSUS TERIFLUNOMIDE ADMINISTERED ORALLY IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS | Novartis Pharmaceuticals Corporation | $20.0M | 0 |
| A SINGLE-ARM, PROSPECTIVE, MULTI-CENTER STUDY TO EXPLORE MAINTAINED EFFICACY WITH OFATUMUMAB THERAPY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS WHO DISCONTINUE INTRAVENOUSLY DELIVERED ANTI-CD20 MONOCLONAL ANTIBODY (ACD20 MAB) THERAPY (OLIKOS) | Novartis Pharmaceuticals Corporation | $17.2M | 0 |
| A SINGLE-ARM, PROSPECTIVE, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE OFATUMUMAB TREATMENT EFFECTIVENESS AND PATIENT REPORTED OUTCOMES IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS TRANSITIONING FROM DIMETHYL FUMARATE OR FINGOLIMOD THERAPY | Novartis Pharmaceuticals Corporation | $14.0M | 0 |
| AN OPEN LABEL STUDY TO ASSESS RESPONSE TO INFLUENZA VACCINE IN OFATUMUMAB TREATED PATIENTS. | Novartis Pharmaceuticals Corporation | $3.3M | 2 |
| AGNOS AN 18-MONTH, OPEN-LABEL, MULTI-CENTER STUDY TO ASSESS THE EFFECT OF OFATUMUMAB 20MG SC MONTHLY IN TREATMENT NAIVE, VERY EARLY RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS BENCHMARKED AGAINST HEALTHY CONTROLS ON SELECT OUTCOMES | Novartis Pharmaceuticals Corporation | $2.8M | 0 |
| AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS | NOVARTIS PHARMACEUTICALS CORPORATION | $2.0M | 0 |
| A 12 WEEK RANDOMIZED OPEN LABEL PARALLEL GROUP MULTICENTER STUDY TO EVALUATE BIOEQUIVALENCE OF 20 MG SUBCUTANEOUS OFATUMUMAB INJECTED BY PRE-FILLED SYRINGE OR AUTOINJECTOR IN ADULT RMS PATIENTS | Novartis Pharmaceuticals Corporation | $2.0M | 0 |
| ANALYSIS OF LYMPHATIC FLUID FROM THE THORACIC DUCT OF HEALTHY SUBJECTS AND PATIENTS WITH MS BEFORE AND DURING OFATUMUMAB TREATMENT | Novartis Pharmaceuticals Corporation | $1.4M | 0 |
| AN OPEN-LABEL MULTICENTER STUDY TO ASSESS RESPONSE TO COVID-19 VACCINE IN PARTICIPANTS WITH MULTIPLE SCLEROSIS TREATED WITH OFATUMUMAB 20 MG SUBCUTANEOUSLY | Novartis Pharmaceuticals Corporation | $1.2M | 0 |
| PHASE II STUDY OF THE HYPER CVAD REGIMEN IN COMBINATION WITH OFATUMUMAB AS FRONTLINE THERAPY FOR PATIENTS WITH CD20 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA | Novartis Pharmaceuticals Corporation | $905,968 | 0 |
| OPEN-LABEL, OBSERVATIONAL, PROSPECTIVE, 9-MONTH STUDY TO ASSESS THE EFFICACY OF OFATUMUMAB ON MICROGLIA IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS | Novartis Pharmaceuticals Corporation | $842,450 | 0 |
| A PILOT OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALL EL-ARM, OF ACUTE VS DELAY OFATUMUMAB TREATMENT D URING AN ACUTE MULTIPLE SCLEROSIS RELAPSE | Novartis Pharmaceuticals Corporation | $810,469 | 0 |
| COMB157G2011R | Novartis Pharma AG | $600,000 | 0 |
| PHASE II TRIAL OF OFATUMUMAB AND FRESH PLASMA IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA. | Novartis Pharmaceuticals Corporation | $538,985 | 0 |
| OFATUMUMAB IN COMBINATION WITH GLUCOCORTICOIDS FOR PRIMARY THERAPY OF CHRONIC GRAFT VS HOST DISEASE | Novartis Pharmaceuticals Corporation | $431,277 | 0 |
| COMB157G2304R | Novartis Pharma AG | $328,036 | 0 |
| Open-label, observational, prospective, 9-month study to assess the efficacy of Ofatumumab on microglia in patients with relapsing forms of multiple sclerosis | Novartis Pharmaceuticals Corporation | $276,667 | 0 |
| PHASE I AND OR II STUDY OF BENDAMUSTINE IN COMBINATION WITH OFATUMUMAB CARBOPLATIN AND ETOPOSIDE FOR REFRACTORY OR RELAPSED AGGRESSIVE B CELL LYMPHOMAS | Novartis Pharmaceuticals Corporation | $257,339 | 0 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF OFATUMUMAB INJECTION FOR SUBCUTANEOUS USE IN SUBJECTS WITH PEMPHIGUS VULGARIS | Novartis Pharmaceuticals Corporation | $255,206 | 0 |
Top Doctors Receiving Payments for ARZERRA — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D/PHD | Student in an Organized Health Care Education/Training Program | New York, NY | $7,275 | 1 |
| , MD | Neurology | Burr Ridge, IL | $7,275 | 1 |
| , MD | Neurology | Dallas, TX | $7,275 | 1 |
| , M.D | Neurology | Philadelphia, PA | $7,275 | 1 |
| Adil Javed | Neurology | Chicago, IL | $7,263 | 5 |
| , M.D | Neurology | Saint Louis, MO | $6,905 | 7 |
| , D.O | Neurology | Concord, NH | $6,850 | 1 |
| , M.D | Neurology | Salt Lake City, UT | $6,756 | 5 |
| , MD | Neurology | Aurora, CO | $6,754 | 2 |
| , M.D | Neurology | Brookline, MA | $6,702 | 6 |
| , D.O | Neurology | Las Vegas, NV | $6,653 | 4 |
| , MD | Neurology | Nashville, TN | $6,583 | 6 |
| , M.D | Diagnostic Radiology | Stony Brook, NY | $6,230 | 2 |
| , M.D | Internal Medicine | San Francisco, CA | $6,213 | 3 |
| , MD | Internal Medicine | Baton Rouge, LA | $6,042 | 4 |
| , MD | Neurology | North Haven, CT | $5,820 | 1 |
| , M.D | Specialist | Guaynabo, PR | $5,730 | 8 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Cincinnati, OH | $5,402 | 1 |
| , D.O | Neurology | Owosso, MI | $5,358 | 5 |
| , M.D | Neurology | York, PA | $4,433 | 6 |
| , DO | Neurology | Portland, OR | $4,125 | 1 |
| , MD | Neurology | Houston, TX | $4,125 | 1 |
| , MD | Neurology | Buffalo, NY | $3,942 | 4 |
| , M.D. PH.D | Neurology | Round Rock, TX | $3,918 | 2 |
| , MD, PHD | Neurology | Aurora, CO | $3,759 | 10 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $144.7M
- Total Doctors 150
- Transactions 2,073
About ARZERRA
ARZERRA is a drug associated with $144.7M in payments to 150 healthcare providers, recorded across 2,073 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2023. In 2023, $390,661 was paid across 18 transactions to 9 doctors.
The most common payment nature for ARZERRA is "Unspecified" ($144.5M, 99.9% of total).
ARZERRA is associated with 20 research studies, including "AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS" ($72.6M).